Compare OTEX & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTEX | SYRE |
|---|---|---|
| Founded | 1991 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.5B |
| IPO Year | 1998 | 2015 |
| Metric | OTEX | SYRE |
|---|---|---|
| Price | $23.44 | $95.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $36.10 | ★ $85.08 |
| AVG Volume (30 Days) | 1.5M | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.94 | N/A |
| Revenue | ★ $2,815,241,000.00 | N/A |
| Revenue This Year | $2.82 | N/A |
| Revenue Next Year | $1.04 | N/A |
| P/E Ratio | $11.70 | ★ N/A |
| Revenue Growth | ★ 22.88 | N/A |
| 52 Week Low | $19.78 | $14.51 |
| 52 Week High | $39.90 | $105.09 |
| Indicator | OTEX | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 56.33 | 56.07 |
| Support Level | $21.82 | $66.78 |
| Resistance Level | $23.70 | $102.06 |
| Average True Range (ATR) | 0.74 | 5.74 |
| MACD | 0.13 | 0.09 |
| Stochastic Oscillator | 86.68 | 50.05 |
Open Text Corp is engaged in the design, development, marketing, and sale of Information Management software and solutions. Its software allows clients to archive, aggregate, retrieve, and search unstructured information (such as documents, e-mail, and presentations). Its platform and services provide secure and scalable solutions for enterprises, SMBs, governments, and consumers around the world. The company's solutions are marketed and delivered on the OpenText Cloud Platform, which is a comprehensive Information Management platform consisting of six business clouds; Content Cloud, Cybersecurity Cloud, Application Automation Cloud, Business Network Cloud, IT Operations Management Cloud, and Analytics Cloud. Geographically, it derives maximum revenue from the United States.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.